Azure Holdings PLC
02 October 2006
Azure Holdings plc
Result of EGM
On 11 September 2006, Azure Holdings plc ('Azure' or the 'Company') announced
that it had agreed, subject, inter alia, to Shareholder approval, to acquire the
entire issued share capital of ValiRx Limited, a biopharmaceutical development
company that is looking to exploit opportunities in the healthcare, life
sciences and biopharmaceutical industries.
At the Extraordinary General Meeting and Class Meetings of Azure, which took
place earlier today, all resolutions put to Shareholders to effect the Capital
Reorganisation and Acquisition were duly approved.
It is expected that Admission will become effective and that dealings in the new
ordinary shares of 0.2p each will commence on AIM on 3 October 2006. The change
of name to ValiRx plc is now expected to be effective from 4 October 2006.
All terms used in this announcement are defined as set out in the admission
document dated 8 September 2006.
For further information:
Gerry Desler, Azure Holdings plc Tel: 01277 366 558
David Youngman, WH Ireland Limited Tel: 0161 832 2174
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.